REFERENCES
- Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–671.
- Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72:333–337.
- Ebrahimkhani MR, Kiani S, Oakley F, Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut. 2006;55:1606–1616.
- Gironi M, Martinelli-Boneschi F, Sacerdote P, A pilot trial of low dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14:1076–1083.
- Hawkes ND, Rhodes J, Evans BK, Naloxone treatment for irritable bowel syndrome—a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16:1649–1654.
- Smith JP, Stock H, Bingaman S, Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102:820–828.
- Paquette J, Olmstead M. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception. Behav Pharmacol. 2005;16:597–603.
- Cruciani RA, Lussier D, Miller-Saultz D, Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage. 2003;25:491–494.
- Hamann S, Sloan PA, Witt W. Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: a case report. J Opioid Manage. 2008;4:251–254.
- McNaull B, Trang T, Sutak M, Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists. Eur J Pharmacol. 2007;560:132–141.
- Largent-Milnes TM, Guo W, Wang H-Y, Oxycodone plus ultralow-dose naltrexone attenuates neuropathic pain and associated μ-opioid receptor—Gs coupling. J Pain. 2008;9:700–713.
- Meissner W, Schmidt U, Hartmann M, Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105–109.
- Kaufman PN, Krevsky B, Malmud LS, Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988;94:1351–1356.
- Geeraerts B, Mimidis K, van Oudenhove L, Role of endogenous opioids in the control of gastric sensorimotor function. Neurogastroenterol Motil. 2008;20:1094–1102.
- Thomas J, Karver S, Cooney GA, Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332–2343.
- Webster L, Jansen JP, Peppin J, Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428–440.
- Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8-3H in normal and narcotic dependent men. J Pharmacol Exp Ther. 1973;187:575–580.
- Nadstawek J, Leyendecker P, Hopp M, Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62:1159–1167.
- Sykes NP. Oral naloxone in opioid-associated constipation. Lancet. 1991;337:1475.
- Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135–144.
- Netzer P, Sendensky A, Wissmeyer MP, The effect of naloxone-3-glucuronide on colonic transit time in healthy men after acute morphine administration: a placebo- controlled double-blinded crossover preclinical volunteer study. Aliment Pharmacol. Ther. 2008;28:1334–1341.
- Reimer K, Hopp M, Zenz M, Meeting the challenges of opioid-induced constipation in chronic pain management—a novel approach. Pharmacology. 2009;83:10–17.
- Meissner W, Leyendecker P, Mueller-Lissner S, A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64.